Novo Nordisk launches affordable Ozempic alternative in South Africa as GLP-1 drugs gain traction across Africa

Novo Nordisk has announced the launch of Extensior, a lower-cost authorised version of its blockbuster diabetes drug Ozempic, in South Africa from 27 July. The move represents a significant strategy shift as the Danish pharmaceutical company responds to mounting pressure from unregulated compounded medicines, generic competitors, and rival treatments flooding Africa's fastest-growing pharma market.

Extensior contains the same active ingredient as Ozempic—semaglutide—and will be available in identical doses (0.25 mg, 0.5 mg and 1 mg). Unlike conventional generics, the product is manufactured by Novo Nordisk using the same production process and injection device as the original, but marketed under a different brand name through a partnership with Swiss pharmaceutical company Acino. Although pricing has not been disclosed, Novo confirmed that Extensior will cost significantly less than branded semaglutide.

Why it matters for Ghana

The launch in South Africa signals a broader shift in how premium pharmaceutical products are being distributed across Africa. As GLP-1 receptor agonist drugs—used to treat type 2 diabetes and obesity—become increasingly sought after on the continent, pharmaceutical companies are adapting their strategies to balance affordability with profit margins. Ghana, with its growing middle class and rising prevalence of diabetes and obesity, is likely to monitor developments in the South African market closely. If Novo Nordisk's strategy proves successful in expanding access while maintaining regulatory compliance, similar approaches could eventually reach West African markets, including Ghana's.

The broader context is critical: South Africa's GLP-1 market has expanded dramatically, tripling to approximately $134 million in just 18 months, reflecting surging demand across Africa for these treatments. This expansion has created opportunities for both legitimate pharmaceutical innovation and unregulated market players, pushing regulators and companies to act swiftly.

The regulatory battle and market dynamics

Extensior's launch follows Novo Nordisk's court victory against iDexis, a South African pharmacy group accused of manufacturing unregistered semaglutide medicines on a commercial scale. In June, South Africa's Gauteng High Court issued an interim order preventing iDexis from producing and selling compounded semaglutide products. Regulators discovered that the pharmacy had been producing approximately 84,500 units monthly—far exceeding the legal threshold for individual patient compounding.

This legal action underscores a critical tension in African pharmaceutical markets: whilst high prices limit access for ordinary patients, they also create incentives for unregulated producers to fill the gap. South African law permits pharmacy compounding for individual patient needs but prohibits large-scale commercial manufacturing under this exemption. The regulatory authority's inspection of iDexis uncovered serious compliance failures and seized products, yet the incident highlights how affordable alternatives remain desperately needed.

Competition intensifying across the continent

Novo Nordisk is not operating in isolation. The company faces fierce competition from Eli Lilly's Mounjaro and newly approved generics from Indian manufacturers like Sun Pharma. By launching Extensior ahead of potential patent expiries and generic competition, Novo aims to maintain market dominance whilst expanding access—a strategy that could reshape how premium medicines are priced and distributed across Africa.

For Ghanaians and other West Africans, these developments in South Africa offer valuable lessons about the future direction of diabetes and obesity treatment access on the continent.